Public HIV Drug Resistance Database
公共艾滋病毒耐药数据库
基本信息
- 批准号:7120407
- 负责人:
- 金额:$ 64.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): HIV drug resistance data are critical for HIV drug resistance surveillance, antiretroviral drug design, and the management of persons infected with drug-resistant HIV. Three fundamental types of correlations form the basis of drug resistance knowledge: (1) Correlations between genotypic data with the treatments of persons from whom sequenced HIV-1 isolates have been obtained (genotype-treatment); (2) Correlations between genotype and in vitro drug susceptibility (genotype-phenotype); and (3) Correlations between genotype and the clinical response to a new treatment regimen (genotype-outcome). Accordingly our three plans are as follows: (1) To use phylogenetically-based statistical analysis of correlations between mutations in the targets of HIV therapy (genotype) and antiretroviral treatment to distinguish between drug- and non-drug- related HIV-1 evolution, to identify temporal and geographic patterns in the prevalence of drug resistance, and to identify the spread of viruses with particular patterns of drug-resistance mutations. (2) To use patterns of mutations in the targets of antiretroviral therapy, antiretroviral treatment data, and in vitro drug susceptibility results to help prioritize the clinical development of experimental antiretroviral compounds. (3) To us correlations between genotype-phenotype and genotype-clinical outcome to identify the treatment regimens most likely to be effective in persons with acquired or transmitted drug resistance. In order to accomplish these aims, we will expand the online publicly available Stanford HIV RT and Protease Sequence Database to represent, store, and analyze the diverse forms of data underlying drug resistance knowledge. Standardized protocols for exchanging data with the broad community of researchers studying HIV-1 drug resistance will be refined and validated. Improved methods for representing published drug resistance data, performing temporal queries and knowledge discovery, and for analyzing genotypic resistance data in a phylogenetic context will be implemented. This proposal is also the start of a three-way collaboration between Stanford University, the University College of London (UCL), and Oxford University. UCL is on the forefront of research into the problem of transmitted drug resistance and Oxford University is on the forefront of research on virus evolution and population genetics.
描述(由申请人提供):HIV耐药性数据对于HIV耐药性监测、抗逆转录病毒药物设计和耐药HIV感染者的管理至关重要。三种基本类型的相关性构成了耐药性知识的基础:(1)基因型数据与已获得HIV-1分离株测序的患者的治疗之间的相关性(基因型-治疗);(2)基因型与体外药物敏感性之间的相关性(基因型-表型);(3)基因型与对新治疗方案的临床应答之间的相关性(基因型-结局)。因此,我们的三个计划如下:(1)使用基于遗传学的统计分析HIV治疗靶点(基因型)和抗逆转录病毒治疗靶点突变之间的相关性,以区分药物相关和非药物相关的HIV-1进化,确定耐药性流行的时间和地理模式,并确定具有特定耐药性突变模式的病毒的传播。(2)利用抗逆转录病毒治疗靶点的突变模式、抗逆转录病毒治疗数据和体外药物敏感性结果,帮助优先考虑实验性抗逆转录病毒化合物的临床开发。(3)利用基因型-表型和基因型-临床结果之间的相关性,以确定对获得性或传播性耐药患者最有效的治疗方案。为了实现这些目标,我们将扩展在线公开的斯坦福大学HIV RT和蛋白酶序列数据库,以表示、存储和分析各种形式的耐药知识数据。将完善和验证与研究HIV-1耐药性的广大研究人员交换数据的标准化协议。将实施用于表示已发表的耐药数据、执行时间查询和知识发现以及用于在系统发育背景下分析基因型耐药数据的改进方法。这一提议也是斯坦福大学、伦敦大学学院(UCL)和牛津大学之间三方合作的开始。伦敦大学学院是研究传播耐药性问题的前沿,牛津大学是研究病毒进化和群体遗传学的前沿。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT William SHAFER其他文献
ROBERT William SHAFER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT William SHAFER', 18)}}的其他基金
HIV-1 Leader Mutations During RT Inhibitor Therapy
RT 抑制剂治疗期间的 HIV-1 领导突变
- 批准号:
9981647 - 财政年份:2019
- 资助金额:
$ 64.54万 - 项目类别:
相似海外基金
Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance
通过创新治疗方案最大限度地减少耐药性,延长抗真菌药物的效用和持久性
- 批准号:
MR/Y002164/1 - 财政年份:2024
- 资助金额:
$ 64.54万 - 项目类别:
Research Grant
New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
基于肽酶刺激的新方法用于靶向耐药性乳腺癌
- 批准号:
10713648 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance
光滑念珠菌抗真菌药物耐药性中蛋白激酶的功能和转录组分析
- 批准号:
10643423 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
RNA m6A修饰在前列腺癌发病及耐药中的作用及机制
- 批准号:
10638634 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models
从高分辨率分子动力学和序列共变模型推断出 HIV 适应性和耐药性的机制
- 批准号:
10750627 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Reversing Drug Resistance in Tumors with Clickable Antibody Pairs
利用可点击的抗体对逆转肿瘤的耐药性
- 批准号:
10566266 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Elucidation of prion strain-specific effect of antiprion drugs and drug resistance mechanisms
阐明抗朊病毒药物的朊病毒株特异性作用和耐药机制
- 批准号:
23H02828 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mathematical Modeling of Drug Resistance Evolution and The Optimal Treatment Strategy in EGFR Mutated Lung Cancer
EGFR突变肺癌耐药演化的数学模型及最佳治疗策略
- 批准号:
22KJ0768 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Targeting RAGE in tumor and TME to oppose inflammation and drug resistance in obesity associated ER+ breast cancer
靶向肿瘤和 TME 中的 RAGE,对抗肥胖相关 ER 乳腺癌的炎症和耐药性
- 批准号:
10734834 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Targeting chromosomal insatiability for overcoming drug resistance
针对染色体不饱和性克服耐药性
- 批准号:
23K08200 - 财政年份:2023
- 资助金额:
$ 64.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)